CMC teams can align with Q5A(R2)’s updated guidance to shorten testing timelines and strengthen assurance of participant safety.
John Muganga
Advertisement
John Muganga is senior manager, Regulatory Affairs at ICON plc.
Articles by John Muganga
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
PharmTech Weekly Roundup—June 19, 2026
5